| Drug | Dose | Route | Comments |
| Desmopressin (DDAVP®) |
0.5 micrograms/hour | IV | half-life 75-120 minutes Titrate to decrease urine output to 3-4 cc/kg/hour May be beneficial in patients with an ongoing coagulopathy |
| Vasopressin (Pitressin®) |
0.5-1 milli-units/kg/hour | IV | half-life 10-35 minutes Titrate to decrease urine output to 3-4 cc/kg/hour Hypertension can occur |
| Treatment of diabetes insipidus should consist of pharmacologic management to decrease but not completely stop urine output. Replacement of urine output with 1/4 or 1/2 normal saline should be used in conjunction with pharmacologic agents to maintain serum sodium levels between 130-150 meq/L. | |||
| Levothyroxine (Synthroid®) |
0.8-1.4 micrograms/kg/hour | IV | Bolus dose 1-5 micrograms/kg can be administered Infants and smaller children require a larger bolus and infusion dose |
| Triiodothyronine (T3) |
0.05-0.2 micrograms/kg/hour | IV | |
| Methylprednisolone (Solu-Medrol®) |
20-30 mg/kg | IV | Dose may be repeated in 8-12 hours Fluid retention Glucose intolerance |
| Insulin | 0.05-0.1 units/kg/hour | IV | Titrate to control blood glucose levels to 60-150 mg/dL Monitor for hypoglycemia |
| Hormonal replacement therapy should be considered early in the course of donor management. Use of hormonal replacement therapy may allow weaning of inotropic support and assist with metabolic stability for the pediatric donor. | |||
